Arvind Kush - 21 Oct 2024 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Reporting relationship: Director
Issuer ticker: IKT
Reported as of: 21 Oct 2024
Net transaction value: +$198,650
SEC form: 4
Accepted by SEC: 23 Oct 2024, 19:49:49 UTC
Prior SEC filing: 27 Feb 2024
Next SEC filing: 19 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Milton H. Werner, attorney-in-fact

Key filing fact

Arvind Kush filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 23 Oct 2024.

Key facts

This page summarizes Arvind Kush's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Oct 2024, 19:49.

Change

Previous filing in this sequence was filed on 27 Feb 2024.
Current net transaction value: +$198,650.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IKT transaction

Common Stock

Purchase

Transaction value: $198,650
Shares: +145,000
Change %
Price: $1.37
Shares after: 145,000
Date: 21 Oct 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 21 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $2.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shares vest 50% on each of the first two anniversaries of October 21, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .